ICI treatment in PCa has to date demonstrated less than exciting results; a Phase III trial testing CTLA-4 blockade (Ipilimumab) did not observe any differences in overall survival compared to placebo in CRPC patients (87). This evidence concerns the gene CTLA4 and posterior cortical atrophy.